Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Utrecht University
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Sep 5, 2023
Discovery & Translation
Epitope editing of immunotherapies; plus NovoBiotic’s antibiotic and more
BioCentury’s roundup of translational innovations
BioCentury | Feb 22, 2022
Emerging Company Profile
TargED: targeting thrombotic disorders directly at clotting sites
Dutch start-up with about €40M in funding will advance fusion protein targeting von Willebrand factor for two indications
BioCentury | Feb 2, 2022
Management Tracks
Roche’s William Pao joins Pfizer as CDO
Plus Clevers succeeds Pao at Roche, new CEO, CFO and other changes at Sosei and updates from Biomea, BeiGene, Cortexyme and more
BioCentury | Sep 1, 2021
Regulation
Fewer obligations, increased uptake of Europe’s conditional approval pathway
More companies seek approval via the expedited route as EMA changes its attitude toward risk
BioCentury | Apr 8, 2021
Product Development
Rounding up intranasal COVID-19 vaccines: Data Byte
In the race to develop the next generation of COVID-19 vaccines, at least 22 vaccine programs are being developed with an intranasal route of administration. Intranasal vaccines may provide
BioCentury | Dec 22, 2020
Deals
Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more
Cytokinetics regains European rights from Servier to heart failure programCytokinetics Inc. (NASDAQ:CYTK) regained European rights to heart failure treatment omecamtiv mecarbil from Servier. The deal
BioCentury | Aug 20, 2020
Finance
Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX
Investor appetite for biotech is going strong in both the U.S. and Hong Kong, with Inhibrx and Harmony posting double-digit gains Wednesday after pricing upsized NASDAQ IPOs late Tuesday, and JW and
BioCentury | Nov 16, 2018
Tools & Techniques
Benchtop manufacturing gets smaller
MIT scientists manufacture therapeutic-grade proteins with a benchtop system
BioCentury | Nov 15, 2018
Tools & Techniques
Benchtop manufacturing gets smaller
MIT scientists manufacture therapeutic-grade proteins with a benchtop system
Items per page:
1 - 10 of 35